Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases. Insmed’s DPP1 inhibitor brensocatib ...

Novel DPP1 Inhibitor Improves Bronchiectasis Outcomes — Drug prolonged time to exacerbations in WILLOW study by Salynn Boyles, Contributing Writer September 8, 2020 • 4 min read ...

STOP-COVID19 is the largest completed trial of DPP1 inhibition in humans and we have performed extensive characterization of how DPP1 inhibition affects the immune system's response," noted Dr. Keir.